New Proteomics Database Identifying Protein Interactions in the Human Body Introduced in Europe by AxCell Biosciences and InforMax

ProChart Database(TM) to Make Axcell's Research in Mapping Interactions In

All of the Body's 60-80 Protein Domain Families Available for Drug Discovery

And Other Medical Research Using GenoMax(TM) Advanced Bioinformatics Software



Database Includes AxCell's Map of WW Domain, First Protein Domain Family Ever

To be Mapped, Which is Believed to Affect Health Problems Including

Hypertension, Muscular Dystrophy and Immunodeficiency.



Apr 24, 2001, 01:00 ET from Cytogen Corporation

    PRINCETON, N.J., April 24 /PRNewswire Interactive News Release/ -- The new
 ProChart(TM) Database of protein interactions in the human body will be
 introduced in Europe this week, it was announced today by AxCell Biosciences
 Corporation, a subsidiary of Cytogen Corporation, and InforMax, Inc.
     The database will include the results of AxCell's successful effort to map
 all of the interactions of one of the body's 60-80 protein domain families.
 In January, 2001, AxCell announced the completion of the map of the WW Protein
 Domain, which is believed to have an impact on health problems including
 hypertension, muscular dystrophy and immunodeficiency.  AxCell is working to
 complete the map of all signal transduction protein interactions in the human
 body within four years.
     In March, AxCell introduced ProChart in six cities across the United
 States using InforMax's Protein-Protein Interaction Analysis (PPI) module,
 which will be available in the next release of the GenoMax(TM) enterprise
 bioinformatics platform, the proprietary advanced bioinformatics software from
 InforMax.
     ProChart is a database of protein-to-protein interactions, created using
 AxCell's patented, high-throughput technology, which differs from the most
 widely used method for studying protein interactions called yeast two-hybrid
 (Y2H).  InforMax is currently marketing the ProChart Database to the
 pharmaceutical and biotechnology industries through multi-year subscriptions.
     Marketing activities for ProChart in Europe begin with presentations at
 IBC's Drug Discovery Technology 2001, the multidisciplinary biopharmaceutical
 conference held April 23-26 in Stuttgart, Germany.  AxCell will also again
 participate in a seminar series with our marketing partner, InforMax.  The
 series is scheduled for May in Europe with further details released by
 InforMax shortly.
     Scientists at AxCell identified more than 69,000 different protein
 interactions of the WW domain, the name for one of the human body's specific
 family of proteins and the initial family offered to ProChart database
 subscribers.  In the future, AxCell anticipates adding PDZ and SH3, two domain
 families involved with diseases such as stroke, Alzheimer's, diabetes, cancer,
 HIV and osteoporosis.  The Company will also chart increasingly greater
 portions of the proteome and add these results to ProChart.  Subscription
 rates will be based on the amount and quality of data available.
     "We have been quite pleased with the interest in ProChart in the U.S.,"
 said Brian R. Bullard, vice president and chief information officer of AxCell
 Biosciences.  "Our technology can positively impact numerous steps in research
 and development, such as target identification and validation, which we
 believe will offer high value to ProChart customers."
     In addition to the high-profile Drug Discovery Technology 2001 conference,
 AxCell will be presenting at a number of future events, such as the IBC
 Proteomics 2001 Conference in Philadelphia in May, and Cambridge Healthtech's
 HTT Expo in Philadelphia in June and Beyond Genome 2001 Conference in San
 Francisco, also in June.  InforMax is continuing with the U.S. marketing
 activities for ProChart in the United States, with initial sales contacts and
 follow-up scheduled for the remainder of 2001.
 
     About Cytogen
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company has two principal lines of business: a product-based oncology
 focus and a proteomics drug discovery platform.  Cytogen's expertise in
 monoclonal antibodies and molecular recognition are directed principally to
 the development of novel products for the diagnosis, imaging, staging and
 treatment of prostate cancer and a proteomics-driven drug discovery platform.
 For information regarding currently marketed oncology products and general
 corporate information, visit http://www.cytogen.com.
 
     About AxCell Biosciences
     AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in
 the effort to chart protein-signaling pathways in the human proteome as a
 means of discovering new drug targets.  AxCell is developing a proprietary
 protein-pathway database, the ProChart(TM) database as a discovery and
 development tool for subscribers in the pharmaceutical, biotechnology and
 agricultural industries.  For additional information on AxCell Biosciences,
 visit http://www.axcellbio.com.
 
     About InforMax
     InforMax is a leading global developer of bioinformatics software for
 High-Throughput Research(TM).  InforMax products are used by more than 1650
 research organizations and more than 22,000 individual scientists worldwide
 (as of December 31, 2000) to understand and extract value from the massive
 amounts of data being generated by the Genomic Revolution.  Among the
 Company's customers are 22 of the top 25 pharmaceutical companies.  InforMax
 was founded in 1990 by Alex Titomirov, Ph.D.  Its mission is to speed the pace
 of medical progress by enabling High-Throughput Research(TM), a process for
 compressing the time it takes to discover and validate the biological targets
 most likely to result in breakthrough therapeutics, diagnostics or
 biomolecular interventions to cure or prevent disease.  InforMax
 bioinformatics software solutions enable a full range of gene-to-genome
 analysis, interpretation and data mining.  Its market-leading products include
 Vector NTI(R) Suite, the most widely used software suite for enhancing
 laboratory productivity, and GenoMax(TM) for integrated analysis of genomic
 and proteomic data.  Additional information about InforMax can be found at the
 company's Web site at http://www.informaxinc.com.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995.
 Information in this press release, which is not historical, is forward-looking
 and involves a number of risks and uncertainties including those discussed in
 the Company's 2000 Form 10-K and from time-to-time the Company's other filings
 with the Securities and Exchange Commission.  Investors are cautioned not to
 put any undue reliance on any forward-looking statement.  The Company's actual
 results may differ materially from those anticipated in these forward-looking
 statements.  Factors that may cause such differences include, but are not
 limited to, uncertainties associated with the Company's ability to sustain its
 intellectual property positions on its proteomics technology, and the
 successful development and market acceptance of the technology.  In
 particular, the Company cannot assure you that the protein interaction program
 will result in the commercialization of a successful product.  The Company
 specifically disclaims any intention or duty to update any forward-looking
 statements, and these statements represent the Company's outlook at this time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X24534544
 
 

SOURCE Cytogen Corporation
    PRINCETON, N.J., April 24 /PRNewswire Interactive News Release/ -- The new
 ProChart(TM) Database of protein interactions in the human body will be
 introduced in Europe this week, it was announced today by AxCell Biosciences
 Corporation, a subsidiary of Cytogen Corporation, and InforMax, Inc.
     The database will include the results of AxCell's successful effort to map
 all of the interactions of one of the body's 60-80 protein domain families.
 In January, 2001, AxCell announced the completion of the map of the WW Protein
 Domain, which is believed to have an impact on health problems including
 hypertension, muscular dystrophy and immunodeficiency.  AxCell is working to
 complete the map of all signal transduction protein interactions in the human
 body within four years.
     In March, AxCell introduced ProChart in six cities across the United
 States using InforMax's Protein-Protein Interaction Analysis (PPI) module,
 which will be available in the next release of the GenoMax(TM) enterprise
 bioinformatics platform, the proprietary advanced bioinformatics software from
 InforMax.
     ProChart is a database of protein-to-protein interactions, created using
 AxCell's patented, high-throughput technology, which differs from the most
 widely used method for studying protein interactions called yeast two-hybrid
 (Y2H).  InforMax is currently marketing the ProChart Database to the
 pharmaceutical and biotechnology industries through multi-year subscriptions.
     Marketing activities for ProChart in Europe begin with presentations at
 IBC's Drug Discovery Technology 2001, the multidisciplinary biopharmaceutical
 conference held April 23-26 in Stuttgart, Germany.  AxCell will also again
 participate in a seminar series with our marketing partner, InforMax.  The
 series is scheduled for May in Europe with further details released by
 InforMax shortly.
     Scientists at AxCell identified more than 69,000 different protein
 interactions of the WW domain, the name for one of the human body's specific
 family of proteins and the initial family offered to ProChart database
 subscribers.  In the future, AxCell anticipates adding PDZ and SH3, two domain
 families involved with diseases such as stroke, Alzheimer's, diabetes, cancer,
 HIV and osteoporosis.  The Company will also chart increasingly greater
 portions of the proteome and add these results to ProChart.  Subscription
 rates will be based on the amount and quality of data available.
     "We have been quite pleased with the interest in ProChart in the U.S.,"
 said Brian R. Bullard, vice president and chief information officer of AxCell
 Biosciences.  "Our technology can positively impact numerous steps in research
 and development, such as target identification and validation, which we
 believe will offer high value to ProChart customers."
     In addition to the high-profile Drug Discovery Technology 2001 conference,
 AxCell will be presenting at a number of future events, such as the IBC
 Proteomics 2001 Conference in Philadelphia in May, and Cambridge Healthtech's
 HTT Expo in Philadelphia in June and Beyond Genome 2001 Conference in San
 Francisco, also in June.  InforMax is continuing with the U.S. marketing
 activities for ProChart in the United States, with initial sales contacts and
 follow-up scheduled for the remainder of 2001.
 
     About Cytogen
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company has two principal lines of business: a product-based oncology
 focus and a proteomics drug discovery platform.  Cytogen's expertise in
 monoclonal antibodies and molecular recognition are directed principally to
 the development of novel products for the diagnosis, imaging, staging and
 treatment of prostate cancer and a proteomics-driven drug discovery platform.
 For information regarding currently marketed oncology products and general
 corporate information, visit http://www.cytogen.com.
 
     About AxCell Biosciences
     AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in
 the effort to chart protein-signaling pathways in the human proteome as a
 means of discovering new drug targets.  AxCell is developing a proprietary
 protein-pathway database, the ProChart(TM) database as a discovery and
 development tool for subscribers in the pharmaceutical, biotechnology and
 agricultural industries.  For additional information on AxCell Biosciences,
 visit http://www.axcellbio.com.
 
     About InforMax
     InforMax is a leading global developer of bioinformatics software for
 High-Throughput Research(TM).  InforMax products are used by more than 1650
 research organizations and more than 22,000 individual scientists worldwide
 (as of December 31, 2000) to understand and extract value from the massive
 amounts of data being generated by the Genomic Revolution.  Among the
 Company's customers are 22 of the top 25 pharmaceutical companies.  InforMax
 was founded in 1990 by Alex Titomirov, Ph.D.  Its mission is to speed the pace
 of medical progress by enabling High-Throughput Research(TM), a process for
 compressing the time it takes to discover and validate the biological targets
 most likely to result in breakthrough therapeutics, diagnostics or
 biomolecular interventions to cure or prevent disease.  InforMax
 bioinformatics software solutions enable a full range of gene-to-genome
 analysis, interpretation and data mining.  Its market-leading products include
 Vector NTI(R) Suite, the most widely used software suite for enhancing
 laboratory productivity, and GenoMax(TM) for integrated analysis of genomic
 and proteomic data.  Additional information about InforMax can be found at the
 company's Web site at http://www.informaxinc.com.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995.
 Information in this press release, which is not historical, is forward-looking
 and involves a number of risks and uncertainties including those discussed in
 the Company's 2000 Form 10-K and from time-to-time the Company's other filings
 with the Securities and Exchange Commission.  Investors are cautioned not to
 put any undue reliance on any forward-looking statement.  The Company's actual
 results may differ materially from those anticipated in these forward-looking
 statements.  Factors that may cause such differences include, but are not
 limited to, uncertainties associated with the Company's ability to sustain its
 intellectual property positions on its proteomics technology, and the
 successful development and market acceptance of the technology.  In
 particular, the Company cannot assure you that the protein interaction program
 will result in the commercialization of a successful product.  The Company
 specifically disclaims any intention or duty to update any forward-looking
 statements, and these statements represent the Company's outlook at this time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X24534544
 
 SOURCE  Cytogen Corporation

RELATED LINKS

http://www.cytogen.com